Non-small Cell Lung Carcinoma

• EMA withdrawal · 2022-05-20
  EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.

  The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…

• EMA withdrawal · 2021-07-27
  EMA Withdrawn: Portrazza (necitumumab) — Eli Lilly Nederland B.V.

  Portrazza (necitumumab) has been withdrawn by its marketing authorization holder in the EMA framework.

• EMA withdrawal · 2016-06-22
  EMA Application withdrawn: Xegafri — Clovis Oncology UK Ltd

  The EMA withdrew the Xegafri application from Clovis Oncology UK Ltd for non-small cell lung carcinoma.